Barclays Cuts Charles River Laboratories International (NYSE:CRL) Price Target to $166.00

Charles River Laboratories International (NYSE:CRL) had its price target cut by equities research analysts at Barclays from $205.00 to $166.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the medical research company’s stock. Barclays‘s price target indicates a potential upside of 0.61% from the company’s current price.

A number of other equities research analysts have also recently commented on CRL. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. TD Cowen raised their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. UBS Group restated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Monday, February 3rd. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $197.64.

Charles River Laboratories International Price Performance

Shares of NYSE:CRL opened at $165.00 on Tuesday. The firm’s 50 day moving average price is $174.02 and its 200-day moving average price is $188.99. Charles River Laboratories International has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $8.44 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 5.91 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter in the prior year, the business earned $2.46 EPS. The business’s quarterly revenue was down 1.1% on a year-over-year basis. Equities research analysts expect that Charles River Laboratories International will post 10.16 EPS for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of institutional investors have recently added to or reduced their stakes in CRL. Versant Capital Management Inc grew its holdings in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its holdings in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International in the fourth quarter valued at $37,000. Finally, GeoWealth Management LLC grew its holdings in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 190 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).